136 related articles for article (PubMed ID: 34936925)
1. Ceftaroline versus vancomycin for treatment of acute pulmonary exacerbations of cystic fibrosis in adults.
Esquivel MD; Monogue ML; Smith GS; Finklea JD; Sanders JM
J Glob Antimicrob Resist; 2022 Mar; 28():67-70. PubMed ID: 34936925
[TBL] [Abstract][Full Text] [Related]
2. Ceftaroline vs vancomycin for the treatment of acute pulmonary exacerbations in pediatric patients with cystic fibrosis.
Branstetter J; Searcy H; Benner K; Yarbrough A; Crowder C; Troxler B
Pediatr Pulmonol; 2020 Dec; 55(12):3337-3342. PubMed ID: 32803907
[TBL] [Abstract][Full Text] [Related]
3. Antibiotic management of methicillin-resistant Staphylococcus aureus--associated acute pulmonary exacerbations in cystic fibrosis.
Fusco NM; Toussaint KA; Prescott WA
Ann Pharmacother; 2015 Apr; 49(4):458-68. PubMed ID: 25583881
[TBL] [Abstract][Full Text] [Related]
4. Comparative Effectiveness of Vancomycin Versus Linezolid for the Treatment of Acute Pulmonary Exacerbations of Cystic Fibrosis.
Fusco NM; Meaney CJ; Frederick CA; Prescott WA
Ann Pharmacother; 2020 Mar; 54(3):197-204. PubMed ID: 31658825
[No Abstract] [Full Text] [Related]
5. Association of Vancomycin Trough Concentration With Response to Treatment for Acute Pulmonary Exacerbation of Cystic Fibrosis.
Fusco NM; Francisconi R; Meaney CJ; Duman D; Frederick CA; Prescott WA
J Pediatric Infect Dis Soc; 2017 Sep; 6(3):e103-e108. PubMed ID: 28903517
[TBL] [Abstract][Full Text] [Related]
6. Vancomycin plus ceftaroline for persistent methicillin-resistant Staphylococcus aureus bacteremia.
Kufel WD; Parsels KA; Blaine BE; Steele JM; Mahapatra R; Paolino KM; Thomas SJ
Pharmacotherapy; 2023 Jan; 43(1):15-23. PubMed ID: 36371648
[TBL] [Abstract][Full Text] [Related]
7. Eradication strategy for persistent methicillin-resistant Staphylococcus aureus infection in individuals with cystic fibrosis--the PMEP trial: study protocol for a randomized controlled trial.
Jennings MT; Boyle MP; Weaver D; Callahan KA; Dasenbrook EC
Trials; 2014 Jun; 15():223. PubMed ID: 24925006
[TBL] [Abstract][Full Text] [Related]
8. Activity of Telavancin against Staphylococcus aureus Isolates, Including Those with Decreased Susceptibility to Ceftaroline, from Cystic Fibrosis Patients.
Roch M; Varela MC; Taglialegna A; Rose WE; Rosato AE
Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29914961
[TBL] [Abstract][Full Text] [Related]
9. State of the art in cystic fibrosis pharmacology-Optimization of antimicrobials in the treatment of cystic fibrosis pulmonary exacerbations: I. Anti-methicillin-resistant Staphylococcus aureus (MRSA) antibiotics.
Epps QJ; Epps KL; Young DC; Zobell JT
Pediatr Pulmonol; 2020 Jan; 55(1):33-57. PubMed ID: 31609097
[TBL] [Abstract][Full Text] [Related]
10. Ceftaroline fosamil monotherapy for methicillin-resistant Staphylococcus aureus bacteremia: a comparative clinical outcomes study.
Arshad S; Huang V; Hartman P; Perri MB; Moreno D; Zervos MJ
Int J Infect Dis; 2017 Apr; 57():27-31. PubMed ID: 28131729
[TBL] [Abstract][Full Text] [Related]
11. Multicenter Observational Study of Ceftaroline Fosamil for Methicillin-Resistant Staphylococcus aureus Bloodstream Infections.
Zasowski EJ; Trinh TD; Claeys KC; Casapao AM; Sabagha N; Lagnf AM; Klinker KP; Davis SL; Rybak MJ
Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27895012
[TBL] [Abstract][Full Text] [Related]
12. Use of ceftaroline after glycopeptide failure to eradicate meticillin-resistant Staphylococcus aureus bacteraemia with elevated vancomycin minimum inhibitory concentrations.
Paladino JA; Jacobs DM; Shields RK; Taylor J; Bader J; Adelman MH; Wilton GJ; Crane JK; Schentag JJ
Int J Antimicrob Agents; 2014 Dec; 44(6):557-63. PubMed ID: 25282169
[TBL] [Abstract][Full Text] [Related]
13. Ceftaroline pharmacokinetics and pharmacodynamics in patients with cystic fibrosis.
Barsky EE; Pereira LM; Sullivan KJ; Wong A; McAdam AJ; Sawicki GS; Priebe GP; Goobie SM
J Cyst Fibros; 2018 May; 17(3):e25-e31. PubMed ID: 29103924
[TBL] [Abstract][Full Text] [Related]
14. Carbapenems drive the collateral resistance to ceftaroline in cystic fibrosis patients with MRSA.
Varela MC; Roch M; Taglialegna A; Long SW; Saavedra MO; Rose WE; Davis JJ; Hoffman LR; Hernandez RE; Rosato RR; Rosato AE
Commun Biol; 2020 Oct; 3(1):599. PubMed ID: 33093601
[TBL] [Abstract][Full Text] [Related]
15. Eradication of persistent methicillin-resistant Staphylococcus aureus infection in cystic fibrosis.
Dezube R; Jennings MT; Rykiel M; Diener-West M; Boyle MP; Chmiel JF; Dasenbrook EC
J Cyst Fibros; 2019 May; 18(3):357-363. PubMed ID: 30131297
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of ceftaroline, vancomycin, daptomycin, or ceftaroline plus daptomycin against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model of simulated endocardial vegetations.
Werth BJ; Barber KE; Ireland CE; Rybak MJ
Antimicrob Agents Chemother; 2014 Jun; 58(6):3177-81. PubMed ID: 24663016
[TBL] [Abstract][Full Text] [Related]
17.
Gaikwad V; Gohel T; Panickar S; Chincholkar V; Mangalkar S
Indian J Pathol Microbiol; 2016; 59(4):496-498. PubMed ID: 27721280
[TBL] [Abstract][Full Text] [Related]
18. Ceftaroline versus vancomycin in the treatment of methicillin-resistant Staphylococcus aureus (MRSA) in an experimental MRSA meningitis model.
Mermer S; Turhan T; Bolat E; Aydemir S; Yamazhan T; Pullukcu H; Arda B; Sipahi H; Ulusoy S; Sipahi OR
J Glob Antimicrob Resist; 2020 Sep; 22():147-151. PubMed ID: 32068093
[TBL] [Abstract][Full Text] [Related]
19. Frequency of small-colony variants and antimicrobial susceptibility of methicillin-resistant Staphylococcus aureus in cystic fibrosis patients.
Suwantarat N; Rubin M; Bryan L; Tekle T; Boyle MP; Carroll KC; Jennings MT
Diagn Microbiol Infect Dis; 2018 Apr; 90(4):296-299. PubMed ID: 29343421
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of intermittent dosed intravenous vancomycin in adult persons with cystic fibrosis.
Lindley B; Bhakta Z; Gray K; Watanabe A; Leclair L; Young DC
Pediatr Pulmonol; 2022 Nov; 57(11):2646-2651. PubMed ID: 35836330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
